Zelija Velija-Asimi1, Sebija Izetbegovic2, Jasenko Karamehic3, Jozo Coric4, Mirsad Panjeta4, Amra Macic-Dzankovic2, Jasminka Djelilovic-Vranic5, Amela Dizdarevic-Bostandzic6. 1. Clinic of Endocrinology, Diabetes and Metabolism diseases, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina. zelijav@gmail.com 2. General Hospital "Prim. Dr Abdulah Nakas", Sarajevo, Bosnia and Herzegovina. 3. Department of Clinical Immunology, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina. 4. Clinic for Clinical Biochemistry, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina. 5. Clinic of Neurology, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina. 6. Clinic of Endocrinology, Diabetes and Metabolism diseases, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Abstract
INTRODUCTION:Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation ofincretin hormones. GOAL: To assess the effects oftreatment with DPP-4 inhibitors on glucoregulation and body weight in obese patients with type 2 diabetes mellitus. PATIENTS AND METHODS: The study included 9 females and 9 males with type 2 diabetes (n=18), BMI=31.24 +/- 2,26 kg/m2, mean age 58 +/- 6,8 years. The patients have been thoroughly evaluated before treatment, and 6 months after treatment with DPP-4 inhibitor (sitagliptin) in combination with metformin. RESULTS: After 6 months of treatment with DPP-4 inhibitors in combination with metformin HbAlc (-1,49%)., FBG (-3.75 mmol/L) and PBG (-5.79 mmol/L) significantly reduced (p=0.000). Mean body weight also significantly reduced (-12.5%; p=0.000). Reduction of mean fasting insulin was 5.46 mIU/L or 27% (p=0.000). Mean HOMA-IR change was -1.64 (p=0.000). Also there was significant decreasing of systolic blood pressure (p=0.001), cholesterol (p=0.004), triglycerides (p=0.001), LDL (p=0.002) and increasing of HDL (p=0.002). Hypoglycaemia was not registered in any of the patients. CONCLUSION: These results show that in obese patients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight.
RCT Entities:
INTRODUCTION:Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation ofincretin hormones. GOAL: To assess the effects oftreatment with DPP-4 inhibitors on glucoregulation and body weight in obesepatients with type 2 diabetes mellitus. PATIENTS AND METHODS: The study included 9 females and 9 males with type 2 diabetes (n=18), BMI=31.24 +/- 2,26 kg/m2, mean age 58 +/- 6,8 years. The patients have been thoroughly evaluated before treatment, and 6 months after treatment with DPP-4 inhibitor (sitagliptin) in combination with metformin. RESULTS: After 6 months of treatment with DPP-4 inhibitors in combination with metformin HbAlc (-1,49%)., FBG (-3.75 mmol/L) and PBG (-5.79 mmol/L) significantly reduced (p=0.000). Mean body weight also significantly reduced (-12.5%; p=0.000). Reduction of mean fasting insulin was 5.46 mIU/L or 27% (p=0.000). Mean HOMA-IR change was -1.64 (p=0.000). Also there was significant decreasing of systolic blood pressure (p=0.001), cholesterol (p=0.004), triglycerides (p=0.001), LDL (p=0.002) and increasing of HDL (p=0.002). Hypoglycaemia was not registered in any of the patients. CONCLUSION: These results show that in obesepatients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight.
Authors: Luciana Neves Cosenso-Martin; Luiz Tadeu Giollo-Junior; José Fernando Vilela-Martin Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.889